Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash from Operations (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Cash from Operations for 13 consecutive years, with 679000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 92.09% to 679000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 13504000.0, a 11.52% increase, with the full-year FY2025 number at 13504000.0, up 11.52% from a year prior.
  • Cash from Operations was 679000.0 for Q4 2025 at Niagen Bioscience, down from 3725000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 8583000.0 in Q4 2024 to a low of 7895000.0 in Q2 2021.
  • A 5-year average of 326550.0 and a median of 345500.0 in 2023 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: crashed 22572.73% in 2021, then surged 2577.97% in 2025.
  • Niagen Bioscience's Cash from Operations stood at 4944000.0 in 2021, then surged by 93.37% to 328000.0 in 2022, then skyrocketed by 297.87% to 649000.0 in 2023, then skyrocketed by 1222.5% to 8583000.0 in 2024, then crashed by 92.09% to 679000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Cash from Operations are 679000.0 (Q4 2025), 3725000.0 (Q3 2025), and 1200000.0 (Q2 2025).